During next 5 years Humanitas University will be involved in European Project MEFISTO – Meniscal functionalised scaffold...
Researcher General Biochemistry (BIO/10)
Research Scientist, Laboratory of Immunopharmacology, Humanitas Clinical and Research Center, Milan
Phone +39 02 8224 5132
Academic Background and Education
Antonio Inforzato graduated in Chemistry (Biological Chemistry Curriculum) at the University of Naples “Federico II” (2001) and obtained his PhD in Immunology at the University of Rome “Tor Vergata” (2006). He then completed his training in Biochemistry and Biophysics at the Faculty of Life Sciences, University of Manchester (Manchester, UK), under the supervision of Prof. Anthony J Day (2006-2009). During his doctoral and post-doctoral studies, he carried out research and study activities at the Leiden University Medical Center (Leiden, The Netherlands; 2005) and the Medical Research Council (MRC) Immunochemistry Unit, University of Oxford (Oxford, UK; 2006). He has been the recipient of fellowships from FIRC (Italian Foundation for Cancer Research; 2006-2007), FHR (Humanitas Foundation for Research; 2007), MRC (2008-2009), SEMM (European School of Molecular Medicine; 2009-2011) and INNOCHEM (Innovative Chemokine-based Therapeutic Strategies for Autoimmunity and Chronic Inflammation; 2010). Recently, he participated in the Postgraduate Course in “Epidemiology for Clinical Research” at Humanitas University (2018). Since 2009 he has been a Research Scientist in the Laboratory of Immunopharmacology of the Humanitas Clinical Institute, headed by Dr. Barbara Bottazzi. He was Assistant Professor of Healthcare Professions and Medical Technologies (MED/46) at the University of Milan. Dr. Inforzato is the author of 29 publications in extenso indexed in Pubmed, 2 encyclopedic entries and 1 book chapter, with an average impact factor greater than 7.5 and h-index of 20 (Scopus) and 22 (Google Scholar). He is co-inventor of 2 patents.
Scientific and Research Interests
The scientific interests of Dr. Inforzato primarily focus on structure/function of soluble components of the innate immune system in infectious and degenerative diseases, and in tissue homeostasis. Particular attention is paid to the long pentraxin PTX3, as a paradigm of the innate humoral response, for which Dr. Inforzato implements and coordinates the following lines of research:
- characterization of the structure of PTX3 and its complexes with complement and matrix proteins;
- study of the molecular mechanisms underlying the functional cooperation between pentraxins and the complement system in the immune response to fungal infections (e.g., invasive aspergillosis) and in immunodegenerative diseases (e.g., age-related macular degeneration);
- definition of the role/s of PTX3 and other matrix molecules (TSG-6, IaI, FGF2) in the remodeling of the hyaluronic acid extracellular matrix in inflammatory (e.g., angiogenesis) and inflammatory-like (e.g., ovulation) processes;
- identification of new functional spaces for the soluble effectors of innate immunity in bone physiology (e.g., bone turn-over) and pathology (e.g., osteomyelitis).
Dr. Inforzato has been teaching at the English-language Medical School of Humanitas University since 2016 (until 2017 on the basis of a conventional agreement with the University of Milan, where he was Assistant Professor of Healthcare Professions and Medical Technologies, since 2018 as a member of the Humanitas University Faculty). He currently lectures in:
- Biochemistry (5 credits) – Module of the integrated course “The cell: molecules and processes” (first year). This module presents the main aspects of metabolic biochemistry. Emphasis is placed on the molecular mechanisms that regulate the intra- and inter-organ metabolic flows in relation to the energy demand of the organism, as a dynamic network of fundamental biochemical processes;
- Biochemistry (2 credits) – Module of the integrated course “Body at Work 1” (second year). This module illustrates the processes that support development and specialization of tissues and organs, as well as their response to external stimuli and adaptation. The biochemical mechanisms underlying neurotransmission, remodeling of the extracellular matrix and cytoskeleton, and the metabolic peculiarities of bone, brain and muscle are critically presented and discussed.
To complement and expand his educational offer, Dr. Inforzato coordinates elective activities in the form of seminars (Biochemistry of Nutrition, Metabolic Syndrome) and laboratories (Internships on ad-hoc research projects).
- Grčević D, Sironi M, Valentino S, Deban L, Cvija H, Inforzato A, Kovačić N, Katavić V, Kelava T, Kalajzić I, Mantovani A, Bottazzi B. (2018) The long pentraxin PTX3 plays a role in bone turnover and repair. Front Immunol. 9:417 IF: 5.511
- Swinkels M, Zhang JH, Tilakaratna V, Black G, Perveen R, McHarg S, Inforzato A, Day AJ, Clark SJ (2018) C-reactive protein and pentraxin-3 binding of factor H-like protein 1 differs from complement factor H: implications for retinal inflammation. Sci Rep. 8(1): 1643 IF: 4.609
- Cunha C, Aversa F, Lacerda JF, Busca A, Kurzai O, Grube M, Löffler J, Maertens JA, Bell AS, Inforzato A, Barbati E, Almeida B, Santos e Sousa P, Barbui A, Potenza L, Caira M, Rodrigues F, Salvatori G, Pagano L, Luppi M, Mantovani A, Velardi A, Romani L, Carvalho A (2014) Genetic deficiency of PTX3 and aspergillosis in stem cell transplantation. N Engl J Med. 370(5):421-32 IF: 55.873
- Inforzato A, Baldock C, Jowitt TA, Holmes DF, Lindstedt R, Marcellini M, Rivieccio V, Briggs DC, Kadler KE, Verdoliva A, Bottazzi B, Mantovani A, Salvatori G, Day AJ (2010) The angiogenic inhibitor long pentraxin PTX3 forms an asymmetric octamer with two binding sites for FGF2. J. Biol. Chem. 285(23):17681-92 IF: 5.328
- Inforzato A, Rivieccio V, Morreale AP, Bastone A, Salustri A, Scarchilli L, Verdoliva A, Vincenti S, Gallo G, Chiapparino C, Pacello L, Nucera E, Serlupi-Crescenzi O, Day AJ, Bottazzi B, Mantovani A, De Santis R, Salvatori G (2008) Structural characterization of PTX3 disulfide bond network and its multimeric status in cumulus matrix organization. J. Biol. Chem. 283(15):10147-61 IF: 5.520
ORCID ID: 0000-0001-8110-0027
Years (from – to): 2019 -2021, Project title: “Role of the long pentraxin PTX3 in osteomyelitis”
Funding body: “Beppe and Nuccy Angiolini” Foundation
Role in the project: PI, Amount of funding: € 360,000
Years (from – to): 2014 -2018, Project title: “The long pentraxin PTX3 as a functional ancestor of antibodies in the immune response to Aspergillus fumigatus”
Funding body: Italian Ministry of Health
Role in the project: PI, Amount of funding: € 330,687.76